Trial Profile
A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of Somatuline (lanreotide) Autogel to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms CALM-NET
- Sponsors Ipsen Limited
- 11 Mar 2020 According to a Ipsen media release, data from this trial will be presented at the during the 17 th European Neuroendocrine Tumor Society (ENETS) Annual Conference, taking place virtually worldwide, (March 11-13, 2020).
- 29 Sep 2017 Status changed from active, no longer recruiting to completed.
- 07 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.